Abstract: Antibodies and antigen binding fragments thereof that immunospecifically bind OPN (OPN) and inhibit OPN activity are provided herein. The disclosed antibodies and antigen binding fragments are useful for modulating signal transduction through OPN proteins. The antibodies and antigen-binding fragments are useful for the treatment or prevention of cancer, osteoporosis, or other immune diseases.

Abstract: Antibodies and antigen binding fragments thereof that immunospecifically bind OPN (OPN) and inhibit OPN activity are provided herein. The disclosed antibodies and antigen binding fragments are useful for modulating signal transduction through OPN proteins. The antibodies and antigen-binding fragments are useful for the treatment or prevention of cancer, osteoporosis, or other immune diseases.

Abstract: Antibodies and antigen binding fragments thereof that immunospecifically bind OPN (OPN) and inhibit OPN activity are provided herein. The disclosed antibodies and antigen binding fragments are useful for modulating signal transduction through OPN proteins. The antibodies and antigen-binding fragments are useful for the treatment or prevention of cancer, osteoporosis, or other immune diseases.

Abstract: Compositions for the inhibition of SUV39H1 methyltransferase activity and methods of use thereof are provided. The disclosed compositions may be used for treating certain types of cancer, inducing apoptosis in a cancer cell, increasing cell sensitivity to FasL-induced apoptosis, and overcoming cancer cell resistance to apoptosis and/or certain types of cancer immunotherapy.

Abstract: Compositions for the inhibition of SUV39H1 methyltransferase activity and methods of use thereof are provided. The disclosed compositions may be used for treating certain types of cancer, inducing apoptosis in a cancer cell, increasing cell sensitivity to FasL-induced apoptosis, and overcoming cancer cell resistance to apoptosis and/or certain types of cancer immunotherapy.

Abstract: Ceramide analogs and methods of their use are provided.

Abstract: Sphingolipid metabolite mimetics and methods of synthesizing them are provided. The sphingolipid metabolite mimetics are shown to be effective at inducing apoptosis in various types of tumor cells. Further, the sphingolipid metabolite mimetics are shown to be effective at sensitizing multiple types of tumor cells to TRAIL-induced apoptosis. Formulations containing one or more sphingolipid metabolite mimetics and, optionally, one or more cell death receptor agonists are provided. Methods of treating cancer in a subject in need thereof are provided using one or more sphingolipid metabolite mimetics.

Abstract: Verticillin A is found to be a potent inhibitor of histone methyltransferases, selective for G9a, GLP, SUV39H1, SUV39H2, MLL1, and NSD2. Methods of using Verticillin A are provided. The Verticillin A can be synthetically produced or it can be isolated from natural sources. Methods if inhibiting one or more histone methyltransferases are provided. In addition, methods are provided for treating diseases or disorders related to overexpression of one or more histone methyltransferases. Exemplary diseases and disorders to be treated include cancer, asthma, HIV, and progeria.

Abstract: Compositions containing epidithiodioxopiprazines and methods of their use are provided. Epidithiodioxopiprazines can be isolated from natural resources or synthesized de novo. Moreover, epidithiodioxopiprazines, including Verticillin A, are shown to effectively sensitize multiple types of tumor cells to TRAIL-induced apoptosis. In addition, epidithiodioxopiprazines, including Verticillin A, are shown to effectively overcome cancer cell resistance to existing drugs (i.e. Etoposide, Cisplatin, 5-FU and Doxorubicin). Therefore, compositions and methods are provided for use in sensitizing target cancer cells to death receptor- and other anticancer drugs-induced apoptosis. Methods of treating cancer in a subject in need thereof are also provided.

Abstract: A system and method for implementing controlled multicast, wherein comprises Ethernet switch 1, multicast router 2, as well as portal server 3 and AAA server 4 that connect with the multicast router, where Ethernet switch 1 connects with each hosts of user in a downlink, in an uplink connects with multicast router 5 and implements multicast switch of layer 2; portal server 3 is used as an interface for access authentication of the user, AAA server 4 is used to store configuration of user privilege for joining in a multicast group; multicast router 2 connects with multicast router 5 of other systems in the uplink, and cooperates together with AAA server 4 to completes privilege authentication for the user when he joins in the multicast group, distributes a control command according to results of the authentication, and controls forwarding of the multicast made by Ethernet switch 1.

Abstract: A system and method for implementing controlled multicast, wherein comprises Ethernet switch 1, multicast router 2, as well as portal server 3 and AAA server 4 that connect with the multicast router, where Ethernet switch 1 connects with each hosts of user in a downlink, in an uplink connects with multicast router 5 and implements multicast switch of layer 2; portal server 3 is used as an interface for access authentication of the user, AAA server 4 is used to store configuration of user privilege for joining in a multicast group; multicast router 2 connects with multicast router 5 of other systems in the uplink, and cooperates together with AAA server 4 to completes privilege authentication for the user when he joins in the multicast group, distributes a control command according to results of the authentication, and controls forwarding of the multicast made by Ethernet switch 1.